Real-world comparison of time to next treatment for patients with high-risk CLL/SLL in first line of treatment

被引：0
|
作者：
Hou, Jing-Zhou
Li, John
Vasudevan, Anupama
Gart, Mike
Choksi, Rushir J.
Blanc, Simon
机构：
[1] Univ Pittsburgh Med Ctr UPMC, Pittsburgh, PA USA
[2] Integra Connect PrecisionQ, W Palm Beach, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19027
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First line treatment of adult patients with primary immune thrombocytopenia: a real-world study
    Wang, Liang
    Xu, Lei
    Hao, Hongyuan
    Jansen, A. J. Gerard
    Liu, Guoqiang
    Li, Honglei
    Liu, Xinguang
    Zhao, Yajing
    Peng, Jun
    Hou, Ming
    PLATELETS, 2020, 31 (01) : 55 - 61
  • [22] Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
    Ortiz Velez, C.
    Villacampa Javierre, G.
    Zamora, E.
    Garcia Alvarez, A.
    Illescas, D. G.
    Viaplana, C.
    Batista, M.
    Martinez, M.
    Garcia-Patos, V.
    Bodet-Castillo, D.
    Ferrer Fabregas, B.
    Recio, J. A.
    Hernandez Losa, J.
    Villalobos Alberu, X.
    Dienstmann, R.
    Munoz-Couselo, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S1412 - S1412
  • [23] Real-world first-line (1L) treatment patterns in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)
    Gupta, S.
    Hong, A.
    El-Chaar, N. N.
    Young, C.
    Ramaswamy, K.
    Xie, B.
    Bunner, S.
    Diessner, B.
    Swami, U.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1190 - S1190
  • [24] Determining first-line CLL/SLL treatment strategies with optimized efficacy and safety
    Mehta, Amitkumar
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (SUPPL 2) : S14 - S19
  • [25] Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
    Narezkina, Anna
    Lu, Xiaoxiao
    Emond, Bruno
    Cote-Sergent, Aurelie
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    BLOOD, 2021, 138
  • [26] Repeat cardiovascular-related procedures and real-world treatment in high-risk patients with hypercholesterolemia or mixed dyslipidemia
    Lehrke, Michael
    Mueller, Sabrina
    Maywald, Ulf
    Deiters, Barthold
    Fraass, Uwe
    Stein, Alexandra
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1583 - 1596
  • [27] Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence.
    Livingstone, Elisabeth
    Forschner, Andrea
    Hassel, Jessica Cecile
    Wulfken, Lena M.
    Meier, Friedegund Elke
    Mohr, Peter
    Kaehler, Katharina C.
    Schilling, Bastian
    Loquai, Carmen
    Berking, Carola
    Huening, Svea
    Eckardt, Julia
    Gutzmer, Ralf
    Reinhardt, Lydia
    Kowall, Bernd
    Galetzka, Wolfgang
    Hauschild, Axel
    Zimmer, Lisa
    Schadendorf, Dirk
    Lodde, Georg
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] REAL-WORLD EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB COMBINATION TREATMENT IN HIGH-RISK PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Woo, Hyun Young
    Hwang, Sangyoun
    Heo, Jeong
    Kim, Hyung Jun
    Park, Young Joo
    Yi, Ki Youn
    Lee, Yu Rim
    Park, Soo Young
    Chung, Woo Jin
    Jang, Byoung-Kuk
    Tak, Won Young
    HEPATOLOGY, 2023, 78 : S1880 - S1881
  • [29] Time to treatment discontinuation and time to next treatment as proxies of real-world progression-free survival in breast cancer patients
    Izano, Monika A.
    Teka, Mander
    Johanson, Colden
    Law, Jeanna Wallenta
    Broome, Ronda
    Morgan, Daniele
    Stone, Amy
    Tran, Mary
    Brown, Thomas D.
    Zhang, Chenan
    CANCER RESEARCH, 2022, 82 (12)
  • [30] Editorial: Biology and treatment of high-risk CLL
    Tausch, Eugen
    Malcikova, Jitka
    Riches, John C.
    Edelmann, Jennifer
    FRONTIERS IN ONCOLOGY, 2023, 12
12345